Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction

Am J Transplant. 2020 Aug;20(8):2058-2069. doi: 10.1111/ajt.15789. Epub 2020 Feb 6.

Abstract

Regulatory T (Treg) cells are important in preventing acute rejection (AR) in solid organ transplantation, but the clinical relevance of the different kinetics early after liver transplantation (LT) in acute rejectors and non-rejectors is unclear. We analyzed peripheral blood samples of 128 LT recipients receiving basiliximab induction plus tacrolimus immunosuppression. Samples were obtained at pretransplant, D7, and D30 after LT. Frequency and phenotype of Tregs were analyzed by flow cytometry. The predictive value of Treg frequency at D7 was assessed for suspected acute rejection (SAR) and was validated for biopsy-proven AR (BPAR). We found that the frequencies of total and activated Tregs at D7 were significantly lower in recipients with SAR and BPAR. Treg was more reduced in BPARs by in vitro tacrolimus treatment in the presence of basiliximab. Moreover, an early reduction of Treg frequency in rejectors was associated with a greater increase in Treg apoptosis and further attenuated IL-2 signaling. D7 Treg frequency was an independent risk factor for SAR, which was also validated for BPAR. In conclusion, first-week peripheral blood Treg frequency correlates with AR after LT under tacrolimus-based immunosuppression, which needs to be proven in larger, geographically and clinically diverse populations.

Keywords: immunobiology; immunosuppressant - calcineurin inhibitor (CNI); immunosuppression/immune modulation; liver transplantation/hepatology; lymphocyte biology; rejection: acute; translational research/science.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Basiliximab
  • Graft Rejection / drug therapy
  • Graft Rejection / etiology
  • Graft Rejection / prevention & control
  • Immunosuppression Therapy
  • Immunosuppressive Agents / therapeutic use
  • Liver Transplantation*
  • T-Lymphocytes, Regulatory
  • Tacrolimus* / therapeutic use

Substances

  • Immunosuppressive Agents
  • Basiliximab
  • Tacrolimus